110 related articles for article (PubMed ID: 21858801)
21. Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy.
Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):147-52. PubMed ID: 19744800
[TBL] [Abstract][Full Text] [Related]
22. The prognostic impact of comorbidities on renal cancer, 1995 to 2006: a Danish population based study.
Lund L; Jacobsen J; Nørgaard M; McLaughlin JK; Blot WJ; Borre M; Sørensen HT
J Urol; 2009 Jul; 182(1):35-40; discussion 40. PubMed ID: 19450859
[TBL] [Abstract][Full Text] [Related]
23. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
D'Amico AV; Hui-Chen M; Renshaw AA; Sussman B; Roehl KA; Catalona WJ
J Urol; 2006 Dec; 176(6 Pt 2):S11-5. PubMed ID: 17084157
[TBL] [Abstract][Full Text] [Related]
24. Differential prognostic impact of comorbidity in head and neck cancer.
Alho OP; Hannula K; Luokkala A; Teppo H; Koivunen P; Kantola S
Head Neck; 2007 Oct; 29(10):913-8. PubMed ID: 17510970
[TBL] [Abstract][Full Text] [Related]
25. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
[TBL] [Abstract][Full Text] [Related]
26. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
Jonsson E; Sigbjarnarson HP; Tomasson J; Benediktsdottir KR; Tryggvadottir L; Hrafnkelsson J; Olafsdottir EJ; Tulinius H; Jonasson JG
Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765
[TBL] [Abstract][Full Text] [Related]
27. The impact of obesity on overall and cancer specific survival in men with prostate cancer.
Davies BJ; Smaldone MC; Sadetsky N; Dall'era M; Carroll PR
J Urol; 2009 Jul; 182(1):112-7; discussion 117. PubMed ID: 19447437
[TBL] [Abstract][Full Text] [Related]
28. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
[TBL] [Abstract][Full Text] [Related]
29. Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer.
Hoffman KE; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin MJ; Ross R; D'Amico AV
Cancer; 2010 Jun; 116(11):2590-5. PubMed ID: 20310055
[TBL] [Abstract][Full Text] [Related]
30. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality.
Freedland SJ; Humphreys EB; Mangold LA; Eisenberger M; Partin AW
J Urol; 2006 Oct; 176(4 Pt 1):1404-8. PubMed ID: 16952644
[TBL] [Abstract][Full Text] [Related]
31. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men.
Gong Z; Agalliu I; Lin DW; Stanford JL; Kristal AR
Cancer; 2007 Mar; 109(6):1192-202. PubMed ID: 17311344
[TBL] [Abstract][Full Text] [Related]
32. Comparison of tumor- and comorbidity-related predictors of mortality after radical prostatectomy.
Froehner M; Koch R; Litz RJ; Haase M; Klenk U; Oehlschlaeger S; Baretton GB; Wirth MP
Scand J Urol Nephrol; 2005; 39(6):449-54. PubMed ID: 16303719
[TBL] [Abstract][Full Text] [Related]
33. Detailed analysis of Charlson comorbidity score as predictor of mortality after radical prostatectomy.
Froehner M; Koch R; Litz RJ; Oehlschlaeger S; Twelker L; Hakenberg OW; Wirth MP
Urology; 2008 Dec; 72(6):1252-7. PubMed ID: 18723211
[TBL] [Abstract][Full Text] [Related]
34. Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities.
Tewari A; Johnson CC; Divine G; Crawford ED; Gamito EJ; Demers R; Menon M
J Urol; 2004 Apr; 171(4):1513-9. PubMed ID: 15017210
[TBL] [Abstract][Full Text] [Related]
35. Salvage radiation in men after prostate-specific antigen failure and the risk of death.
Cotter SE; Chen MH; Moul JW; Lee WR; Koontz BF; Anscher MS; Robertson CN; Walther PJ; Polascik TJ; D'Amico AV
Cancer; 2011 Sep; 117(17):3925-32. PubMed ID: 21437885
[TBL] [Abstract][Full Text] [Related]
36. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.
D'Amico AV; Chen MH; Roehl KA; Catalona WJ
N Engl J Med; 2004 Jul; 351(2):125-35. PubMed ID: 15247353
[TBL] [Abstract][Full Text] [Related]
37. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer.
Zincke H; Lau W; Bergstralh E; Blute ML
J Urol; 2001 Dec; 166(6):2208-15. PubMed ID: 11696737
[TBL] [Abstract][Full Text] [Related]
38. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
39. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival.
Cheville JC; Tindall D; Boelter C; Jenkins R; Lohse CM; Pankratz VS; Sebo TJ; Davis B; Blute ML
Cancer; 2002 Sep; 95(5):1028-36. PubMed ID: 12209687
[TBL] [Abstract][Full Text] [Related]
40. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system.
Buskirk SJ; Pisansky TM; Schild SE; Macdonald OK; Wehle MJ; Kozelsky TF; Collie AC; Ferrigni RG; Myers RP; Prussak KA; Heckman MG; Crook JE; Parker AS; Igel TC
J Urol; 2006 Sep; 176(3):985-90. PubMed ID: 16890677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
